Roche Diagnostics Survey - SARS-CoV-2 Point-of-Care Tests
Rapid Antigen Nasal Professional (for health professionals) and Rapid Antigen Self-Test 

Thank you for your interest in the Roche Diagnostics SARS-CoV-2 Point of Care (POC) tests.

SARS-CoV-2 Rapid Antigen Test Nasal - Nasal Professional Use

Roche SARS-CoV-2 Rapid Antigen Test Nasal has been authorized under Health Canada’s Interim Order last June 21st making it available to Canadian healthcare professionals. The Roche Diagnostics Canada team is currently working on the allocation strategy for the SARS-CoV-2 Rapid Antigen Test Nasal. Please note we’re experiencing a temporary backorder situation and the estimated timeline to resolution is February 2022. If you are an existing customer, we will keep you informed as the situation evolves.

If you are interested in knowing more about Roche rapid COVID-19 tests, please fill out this form to share your questions and interest. You can expect someone from the Point of Care team to follow-up with you as soon as possible to answer your questions and request.

SARS-CoV-2 Rapid Antigen Self-Test Nasal

Roche SARS-CoV-2 Antigen Self Test Nasal has been authorized under Health Canada’s Interim Order on Dec 13, 2021 making it available for home self-test use. The Canadian POC team is currently working on the allocation strategy for the SARS-CoV-2 Antigen Self Test Nasal. This new rapid self-test is commercialized by Roche under an exclusive Global distribution agreement with SD Biosensor Inc.

Please fill out this form to signify your interest and a Roche representative will contact you shortly to provide further information. Due to unprecedented Global demand, we expect these tests to be available for Canadian customers in Q2 2022.